OmniAb raises 2026 revenue guidance after strong third quarter

what happened

OmniAb, a provider of discovery research technology for next-generation therapeutics, published its third-quarter 2026 results, according to TradingView. Revenue reached $4.0 million against $2.2 million a year earlier, driven mainly by service work on antibody and ion channel programs and higher sales of xPloration instruments and consumables. The net loss narrowed to $15.7 million, or $0.12 per share, from $16.5 million, or $0.14 per share. For the nine months, revenue came to $31.8 million, largely due to milestone payments.

The company lifted its 2026 revenue guidance to $35 million to $39 million from $32 million to $36 million, and now expects year-end cash of $53 million to $57 million, up from $49 million to $53 million. Cash, equivalents and short-term investments stood at $64.2 million as of September 30.

why it matters

For investors, the key takeaway is that losses narrowed while a meaningful share of revenue rests on licensing deals and milestone payments. A new Eli Lilly ion channel agreement, with up to $370 million in milestones, underlines that model, and the revenue outlook will be the main gauge of how much growth the company can sustain.

tags

instruments